ALS Treatment via Multi-Pathway Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amyotrophic lateral sclerosis (ALS) remains an incurable disease due to inadequate understanding of disease mechanisms, with existing treatments offering limited benefit in extending survival by only 2-3 months.
Innovation Solution
A method for treating ALS involving the administration of one or more active agents selected from a group consisting of retinoic acid receptor alpha (RARα) agonists, voltage-gated potassium channel (KCNB2) inhibitors, adrenergic receptor α2B (ADRA2B) antagonists, and other specified receptor and enzyme inhibitors, either alone or in combination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing ALS treatments (Riluzole, Edaravone) are used, then patients receive neuroprotective effects, but survival extension is limited to only 2-3 months
Solution Approach 1:
The patent segments the ALS treatment approach by identifying and targeting multiple distinct molecular pathways simultaneously. Instead of relying on a single drug mechanism, the invention uses combination therapy with agents targeting different pathways (e.g., SOD1, TDP-43, C9orf72, FUS, and other protein aggregation pathways), thereby dividing the treatment task into multiple specialized components that collectively extend survival beyond the limited 2-3 months achieved by conventional single-agent therapies.
Solution Approach 2:
The patent applies the composite materials principle by creating a composite therapeutic regimen that combines multiple pharmacological agents with different mechanisms of action. This composite approach integrates neuroprotective agents, anti-aggregation therapies, and pathway-specific inhibitors into a unified treatment strategy, achieving synergistic effects that substantially extend survival time compared to individual monotherapies.
2Reliability
If combination therapy with multiple active agents is used, then treatment effectiveness is improved, but device complexity increases
Solution Approach 1:
The patent applies universality by developing a multi-functional therapeutic platform that can address multiple ALS subtypes and pathological mechanisms through a single combination therapy regimen. The selected active agents are chosen to simultaneously target various protein aggregation pathways (SOD1, TDP-43, C9orf72, FUS) and cellular dysfunction mechanisms, allowing one treatment protocol to serve multiple therapeutic purposes and reducing the need for separate specialized therapies for different ALS variants.
Data Source
AI summary
Provided is a method and a medicament for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, comprising administering to the subject an effective amount of one or more active agents selected from the group consisting of a retinoic acid receptor alpha (RARα) agonist, a voltage-gated potassium channel (KCNB2) inhibitor, an adrenergic receptor α2B (ADRA2B) antagonist, a DNA methyltransferase 3 alpha (DNMT3A) antagonist, an insulin like growth factor 1 receptor (IGF1R) inhibitor, a mitogen-activated protein kinase 1 (MAPK1) inhibitor, a nitric oxide synthase 1 (NOS1) inhibitor, a glucocorticoid receptors (NR3C1) antagonist, and a peptidylprolyl Isomerase A (PPIA) antagonist.